FLT3 as a Target for Drug Discovery to Treat Leukemia View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2001-2005

FUNDING AMOUNT

1356871 USD

ABSTRACT

Our long-term goals are to increase the cure rate and decrease chemotherapy-relate toxicity for patients with leukemia. In particular, we are interested in patients whose leukemias express an activated FLT3 receptor, either as a result of mutation or ligand co-expression. 20% of AML patients have mutations of the FLT3 receptor. These patients have a particularly poor prognosis with almost no one being cured in either the pediatric or adult populations. The mutation of the FLT3 receptor consists of small (18-105 bp) internal tandem duplications (ITDs) which are unique for each patient but all map to the juxtamembrane region of the receptor. These mutations constitutively activate the tyrosine kinase domain of FLT3 receptor which is required for signaling. This makes the development of novel strategies for these patients imperative if we are to effect improvements in their outcome. If FLT3 constitutive activation is contributing to leukemogenesis in these patients, one strategy would be to develop small molecule inhibitors of the kinase domain of the receptor. We therefore propose two major specific aims in this proposal with FLT3 as the novel molecular target for drug discovery. The first id to validate FLT3 as a molecular target by developing several animal models that mimic different ways that the FLT3 can become constitutively activated. We will also introduce second "hits" that often occur in leukemia to study the spectrum of the hematopoietic disease to which an activated FLT3 can contribute. The second aim is to develop assays utilizing cell lines and proteins that can be utilized for high-throughout screening of FLT3 inhibitors. This will enable the discovery of lead compounds that are unable to inhibit FLT3 in a highly potent and specific fashion. We believe that this work will lead to the identification of compounds able to inhibit FLT3 which will ultimately be used as novel therapeutics against leukemia. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=6756426

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "1356871"
    }, 
    "description": "Our long-term goals are to increase the cure rate and decrease chemotherapy-relate toxicity for patients with leukemia. In particular, we are interested in patients whose leukemias express an activated FLT3 receptor, either as a result of mutation or ligand co-expression. 20% of AML patients have mutations of the FLT3 receptor. These patients have a particularly poor prognosis with almost no one being cured in either the pediatric or adult populations. The mutation of the FLT3 receptor consists of small (18-105 bp) internal tandem duplications (ITDs) which are unique for each patient but all map to the juxtamembrane region of the receptor. These mutations constitutively activate the tyrosine kinase domain of FLT3 receptor which is required for signaling. This makes the development of novel strategies for these patients imperative if we are to effect improvements in their outcome. If FLT3 constitutive activation is contributing to leukemogenesis in these patients, one strategy would be to develop small molecule inhibitors of the kinase domain of the receptor. We therefore propose two major specific aims in this proposal with FLT3 as the novel molecular target for drug discovery. The first id to validate FLT3 as a molecular target by developing several animal models that mimic different ways that the FLT3 can become constitutively activated. We will also introduce second \"hits\" that often occur in leukemia to study the spectrum of the hematopoietic disease to which an activated FLT3 can contribute. The second aim is to develop assays utilizing cell lines and proteins that can be utilized for high-throughout screening of FLT3 inhibitors. This will enable the discovery of lead compounds that are unable to inhibit FLT3 in a highly potent and specific fashion. We believe that this work will lead to the identification of compounds able to inhibit FLT3 which will ultimately be used as novel therapeutics against leukemia.", 
    "endDate": "2005-05-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2688965", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2688965"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "U01CA091177"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "mutations", 
      "toxicity", 
      "ligand co-expression", 
      "cure rate", 
      "long-term goal", 
      "spectrum", 
      "outcome", 
      "compounds", 
      "work", 
      "molecular targets", 
      "adult population", 
      "discovery", 
      "hematopoietic diseases", 
      "poor prognosis", 
      "novel", 
      "maps", 
      "development", 
      "identification", 
      "bp", 
      "lead compounds", 
      "results", 
      "novel strategy", 
      "receptors", 
      "second aim", 
      "screening", 
      "AML patients", 
      "drug discovery", 
      "internal tandem duplication", 
      "patients", 
      "specific fashion", 
      "FLT3", 
      "small molecule inhibitors", 
      "several animal models", 
      "protein", 
      "improvement", 
      "one", 
      "Treat Leukemia", 
      "FLT3 receptor", 
      "major specific aims", 
      "assay", 
      "novel therapeutics", 
      "leukemia", 
      "strategies", 
      "decrease chemotherapy", 
      "juxtamembrane region", 
      "different ways", 
      "tyrosine kinase domain", 
      "hits", 
      "proposal", 
      "FLT3 inhibitors", 
      "target", 
      "FLT3 constitutive activation", 
      "cell lines", 
      "kinase domain"
    ], 
    "name": "FLT3 as a Target for Drug Discovery to Treat Leukemia", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.21107.35", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.21107.35", 
          "name": "JOHNS HOPKINS UNIVERSITY", 
          "type": "Organization"
        }, 
        "familyName": "SMALL", 
        "givenName": "DONALD", 
        "id": "sg:person.01226411152.62", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01226411152.62", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2688965"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_19.xml.gz", 
    "startDate": "2001-06-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=6756426"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2688965'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2688965'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2688965'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2688965'


 

This table displays all metadata directly associated to this object as RDF triples.

98 TRIPLES      19 PREDICATES      76 URIs      68 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2688965 schema:about anzsrc-for:2211
2 schema:amount N70af011c1c5d483d8c2032f6d4a68ff0
3 schema:description Our long-term goals are to increase the cure rate and decrease chemotherapy-relate toxicity for patients with leukemia. In particular, we are interested in patients whose leukemias express an activated FLT3 receptor, either as a result of mutation or ligand co-expression. 20% of AML patients have mutations of the FLT3 receptor. These patients have a particularly poor prognosis with almost no one being cured in either the pediatric or adult populations. The mutation of the FLT3 receptor consists of small (18-105 bp) internal tandem duplications (ITDs) which are unique for each patient but all map to the juxtamembrane region of the receptor. These mutations constitutively activate the tyrosine kinase domain of FLT3 receptor which is required for signaling. This makes the development of novel strategies for these patients imperative if we are to effect improvements in their outcome. If FLT3 constitutive activation is contributing to leukemogenesis in these patients, one strategy would be to develop small molecule inhibitors of the kinase domain of the receptor. We therefore propose two major specific aims in this proposal with FLT3 as the novel molecular target for drug discovery. The first id to validate FLT3 as a molecular target by developing several animal models that mimic different ways that the FLT3 can become constitutively activated. We will also introduce second "hits" that often occur in leukemia to study the spectrum of the hematopoietic disease to which an activated FLT3 can contribute. The second aim is to develop assays utilizing cell lines and proteins that can be utilized for high-throughout screening of FLT3 inhibitors. This will enable the discovery of lead compounds that are unable to inhibit FLT3 in a highly potent and specific fashion. We believe that this work will lead to the identification of compounds able to inhibit FLT3 which will ultimately be used as novel therapeutics against leukemia.
4 schema:endDate 2005-05-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier Nd1e19ee71784428f9a8f3988e6de84a4
7 Ne3d6ef09c299412a8e6097ded12cb621
8 schema:inLanguage en
9 schema:keywords AML patients
10 FLT3
11 FLT3 constitutive activation
12 FLT3 inhibitors
13 FLT3 receptor
14 Treat Leukemia
15 adult population
16 assay
17 bp
18 cell lines
19 compounds
20 cure rate
21 decrease chemotherapy
22 development
23 different ways
24 discovery
25 drug discovery
26 hematopoietic diseases
27 hits
28 identification
29 improvement
30 internal tandem duplication
31 juxtamembrane region
32 kinase domain
33 lead compounds
34 leukemia
35 ligand co-expression
36 long-term goal
37 major specific aims
38 maps
39 molecular targets
40 mutations
41 novel
42 novel strategy
43 novel therapeutics
44 one
45 outcome
46 patients
47 poor prognosis
48 proposal
49 protein
50 receptors
51 results
52 screening
53 second aim
54 several animal models
55 small molecule inhibitors
56 specific fashion
57 spectrum
58 strategies
59 target
60 toxicity
61 tyrosine kinase domain
62 work
63 schema:name FLT3 as a Target for Drug Discovery to Treat Leukemia
64 schema:recipient N4c104272567f408ea2e1577a834928bf
65 sg:person.01226411152.62
66 https://www.grid.ac/institutes/grid.21107.35
67 schema:sameAs https://app.dimensions.ai/details/grant/grant.2688965
68 schema:sdDatePublished 2019-03-07T12:07
69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
70 schema:sdPublisher Nc0928b7d9a534a6489ff9159e6301663
71 schema:startDate 2001-06-01T00:00:00Z
72 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=6756426
73 sgo:license sg:explorer/license/
74 sgo:sdDataset grants
75 rdf:type schema:MonetaryGrant
76 N4c104272567f408ea2e1577a834928bf schema:member sg:person.01226411152.62
77 schema:roleName PI
78 rdf:type schema:Role
79 N70af011c1c5d483d8c2032f6d4a68ff0 schema:currency USD
80 schema:value 1356871
81 rdf:type schema:MonetaryAmount
82 Nc0928b7d9a534a6489ff9159e6301663 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 Nd1e19ee71784428f9a8f3988e6de84a4 schema:name dimensions_id
85 schema:value 2688965
86 rdf:type schema:PropertyValue
87 Ne3d6ef09c299412a8e6097ded12cb621 schema:name nih_id
88 schema:value U01CA091177
89 rdf:type schema:PropertyValue
90 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
91 rdf:type schema:DefinedTerm
92 sg:person.01226411152.62 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
93 schema:familyName SMALL
94 schema:givenName DONALD
95 rdf:type schema:Person
96 https://www.grid.ac/institutes/grid.21107.35 schema:name JOHNS HOPKINS UNIVERSITY
97 rdf:type schema:Organization
98 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...